ARESTIN® Rx Access Back

ARESTIN® Rx Access Back

Welcome to the ARESTIN® Rx Access Program

Help Periodontal Patients Get Treatment With ARESTIN® + 
Scaling and Root Planing (SRP)
When Indicated


Introduction to 
ARESTIN® Rx Access


This service may help more patients access ARESTIN® as part of their comprehensive treatment plan that includes SRP.

ARESTIN® Rx Access is a convenient way to find out if patients' medical insurance prescription benefits cover treatment with ARESTIN®.

To get started, view our 3-step process guide and download our patient education tool and necessary forms below.

Forms and Handouts

These program forms from HealthBridge Pharma & BiotechSM and patient education tool help you to more easily implement ARESTIN® Rx Access.

Adobe ReaderTo view these materials, you will need the Adobe® Reader. Click here to download it now.

For Your Office

Prescription Request Form
Prescription Request Form

Use to request coverage determination and prescribe ARESTIN®  for insured patients through ARESTIN®  Rx Access

Credit Card Authorization Form
Credit Card Authorization Form

Patient Credit Card Authorization Form for ARESTIN® prescription co-pay through HealthBridge

Office Guide
Office Guide

Simplified flowchart of the program’s 3-step process

Prescription Tracking Form
Prescription Tracking Form

For Your Patients

Patient Reminder Card

Useful instructions to share with your patients to explain how their co-pay is collected and the importance of returning for their next appointment

For immediate information, call ARESTIN® 

Rx Access Customer Service at 1-855-289-2578.


Enhanced Prescription Tracking Service coming soon. 

INDICATION
ARESTIN® (minocycline HCl) Microspheres, 1 mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION
ARESTIN® should not be used in any patient who has a known sensitivity to minocycline or tetracyclines. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth, and therefore should not be used in children or in pregnant or nursing women. Hypersensitivity reactions that included, but were not limited to, anaphylaxis, angioneurotic edema, urticaria, rash, swelling of the face and pruritus have been reported with the use of ARESTIN®. In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome and pain.

Please read the Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

MyArestinTM is a trademark and ARESTIN® is a registered trademark of OraPharma, Inc.

This site is published by OraPharma, Inc., which is solely responsible for its contents. It is intended for visitors from the United States.

Manufactured for OraPharma, Inc. ©OraPharma, Inc. 2013   A-1373-12   01/13